A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC). The name of the study drugs involved in this research study is: * Sasanlimab (a type of monoclonal antibody) * Palbociclib (a type of kinase inhibitor) * Axitinib (a type of Vascular endothelial growth factor inhibitor)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznanie zaawansowanego lub rozprzestrzenionego raka nerki (typ przezroczystokomórkowy lub translokacyjny), który nie może być operacyjnie usunięty
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG ≤2)
- •Wymieralne zmiany nowotworowe widoczne w badaniach obrazowych
- •Prawidłowe wyniki badań krwi (liczba neutrofili, płytki krwi, hemoglobina)
- •Dostęp do próbki tkanki nowotworu pobrane niedawno (w ciągu ostatniego roku) lub nowa biopsja podczas badań wstępnych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Brigham and Women's Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Trial contact
Stephanie Berg, DO
Bradley McGregor, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.